Press

Jumpcode Genomics Secures $21M in Series B Funding

Investors include Baird Capital, Arboretum Ventures and LYZZ Capital; funding will accelerate commercialization of CRISPRclean™ next-generation sequencing technology Life sciences industry veteran Frank Witney joins Jumpcode Board of Directors Jumpcode opens new headquarters in San Diego biotech business hub   SAN DIEGO, Calif. – Jan. 12, 2021 – Jumpcode Genomics – a genome technology company …

Jumpcode Genomics Secures $21M in Series B Funding Read More »

Q&A: A jump to the next step in sequencing

Kelsey Kaustinen details how Jumpcode’s CRISPRclean technology unites NGS and CRISPR/Cas editing in a Q&A with our Chief Scientist in the current issue of Drug Discovery News. Read on to hear Dr. Nelson’s perspective on how CRISPRclean can benefit life sciences and biopharma industry research. Jumpcode details how its CRISPRclean tech unites NGS and CRISPR/Cas …

Q&A: A jump to the next step in sequencing Read More »

Jumpcode Genomics Exits Stealth Mode, Unveils Technology that Addresses the ‘Needle in the Haystack’ Problem of Molecular Biology

Patented CRISPRclean™ Technology is a Foundational Tool that Improves the Performance of Next-Generation Sequencing and Other Molecular Workflows by Increasing Sensitivity, Reducing Costs and Enabling Novel Discovery CARLSBAD, Calif. – Sept. 17, 2020 – Jumpcode Genomics – a genome technology company founded by industry veterans in 2016 focused on improving the understanding of human disease – today exited stealth mode and …

Jumpcode Genomics Exits Stealth Mode, Unveils Technology that Addresses the ‘Needle in the Haystack’ Problem of Molecular Biology Read More »

Scroll to Top